0001140361-17-001832.txt : 20170113
0001140361-17-001832.hdr.sgml : 20170113
20170113161522
ACCESSION NUMBER: 0001140361-17-001832
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170111
FILED AS OF DATE: 20170113
DATE AS OF CHANGE: 20170113
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 17527897
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
form4.xml
FORM 4
X0306
4
2017-01-11
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54 RUE LA BOETIE
PARIS
I0
75008
FRANCE
true
Common Stock
2017-01-11
4
P
0
1592
362.4664
A
23419988
I
See note
Common Stock
2017-01-11
4
P
0
6546
363.3534
A
23426534
I
See note
Common Stock
2017-01-11
4
P
0
13226
364.3224
A
23439760
I
See note
Common Stock
2017-01-11
4
P
0
19858
365.2018
A
23459618
I
See note
Common Stock
2017-01-11
4
P
0
3979
366.0528
A
23463597
I
See note
Common Stock
2017-01-11
4
P
0
1986
367.2911
A
23465583
I
See note
Common Stock
2017-01-11
4
P
0
2336
368.3472
A
23467919
I
See note
Common Stock
2017-01-11
4
P
0
2517
369.3
A
23470436
I
See note
Common Stock
2017-01-11
4
P
0
900
370.1789
A
23471336
I
See note
Common Stock
2017-01-11
4
P
0
1259
371.5346
A
23472595
I
See note
Common Stock
2017-01-11
4
P
0
2675
372.8741
A
23475270
I
See note
Common Stock
2017-01-11
4
P
0
2784
373.9018
A
23478054
I
See note
Common Stock
2017-01-11
4
P
0
3830
374.5922
A
23481884
I
See note
Common Stock
2017-01-11
4
P
0
3016
375.8789
A
23484900
I
See note
Common Stock
2017-01-11
4
P
0
3851
376.7488
A
23488751
I
See note
Common Stock
2017-01-11
4
P
0
5313
377.8368
A
23494064
I
See note
Common Stock
2017-01-11
4
P
0
9520
378.7635
A
23503584
I
See note
Common Stock
2017-01-11
4
P
0
2110
379.5636
A
23505694
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $361.76 to $362.71 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Purchase prices range from $362.80 to $363.79 per share, inclusive.
Purchase prices range from $363.80 to $364.77 per share, inclusive.
Purchase prices range from $364.80 to $365.79 per share, inclusive.
Purchase prices range from $365.80 to $366.73 per share, inclusive.
Purchase prices range from $366.83 to $367.81 per share, inclusive.
Purchase prices range from $367.84 to $368.78 per share, inclusive.
Purchase prices range from $368.84 to $369.79 per share, inclusive.
Purchase prices range from $369.87 to $370.59 per share, inclusive.
Purchase prices range from $371.05 to $372.02 per share, inclusive.
Purchase prices range from $372.29 to $373.27 per share, inclusive.
Purchase prices range from $373.30 to $374.28 per share, inclusive.
Purchase prices range from $374.31 to $375.24 per share, inclusive.
Purchase prices range from $375.36 to $376.34 per share, inclusive.
Purchase prices range from $376.36 to $377.34 per share, inclusive.
Purchase prices range from $377.36 to $378.35 per share, inclusive.
Purchase prices range from $378.37 to $379.36 per share, inclusive.
Purchase prices range from $379.38 to $379.80 per share, inclusive.
Exhibit 24 - Power of Attorney (incorporated herein by reference to Exhibit 24 to Form 4 filed by the Reporting Person with the SEC on February 3, 2016, with respect to Alnylam Pharmaceuticals, Inc.).
/s/ Alexandra Roger, attorney-in-fact
2017-01-13